Precigen vs Verastem
PGEN and VSTM side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How PGEN and VSTM compare
Precigen is the larger company, worth 2.2 times as much as Verastem ($1.6B against $741M).
Precigen keeps more of each dollar of sales as profit, with a net margin of 15.6% compared with −178% at Verastem.
Precigen scores higher on the StockData Score (6 against 3 for Verastem), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | PGEN | VSTM |
|---|---|---|
| Size and price | ||
| Market cap | $1.6B | $741M |
| Share price | $4.54 | $8.18 |
| Change, 1 year | 12.9% | −3.9% |
| Change, 5 years | 20.7% | −77.0% |
| Beta (5Y) | 1.63 | 1.37 |
| Employees | 20 | 102 |
| StockData Score | ||
| Total score | 6 (better) | 3 |
| Valuation score | 0 | 0 |
| Growth score | 0 | 1 (better) |
| Performance score | 4 (better) | 1 |
| Health score | 2 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 114× | – |
| P/S | 10.4× | 7.4× (better) |
| P/B | 19.4× (better) | 73.3× |
| EV/EBITDA | 43.8× | – |
| FCF yield | −4.6% | – |
| Fair value | $1.34 | – |
| Margin of safety | −239% | – |
| Growth | ||
| Revenue growth, 5Y average | −21.3% | −19.0% (better) |
| Profitability | ||
| Operating margin | 21.4% (better) | −194% |
| Net margin | 15.6% (better) | −178% |
| FCF margin | −47.4% | – |
| Return on equity | 38.8% | – |
| Return on invested capital | 147% | – |
| Financial health | ||
| Debt / equity | 1.12 | – |
| Net debt / EBITDA | 1.14 | – |
| Interest coverage | 2.8× (better) | −141.9× |
| Current ratio | 5.58 (better) | 1.93 |
| Altman Z-score | −5.48 (better) | −7.82 |
| Piotroski F-score | 2 | 4 (better) |
| Dividends and buybacks | ||
| Buyback yield | 0.00% | – |
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 39.2% | 109% |
| Held by insiders | 44.9% | 1.8% |
| Insider net buying, 12 months | −$32.5M | −$816K (better) |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 22.8% | 22.1% |
Go deeper
- PGEN stock overview
- PGEN income statement
- PGEN valuation and score
- VSTM stock overview
- VSTM income statement
- VSTM valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.